Alkermes
demonstrated anti tumor activity in melanoma and renal cell carcinoma dose tumor type prior therapy lines best overall response decrease in target lesions time on therapy weeks continuing therapy mucosal melanoma mucosal melanoma unconfirmed cutaneous melanoma melanoma vaccine renal cell carcinoma renal cell carcinoma placebo awaiting confirmation awaiting confirmation awaiting confirmation yes no yes yes yes data cutoff march reported after data extraction partial response recommended phase dose | Alkermes
Company
Deck Type
Sector
Industry
Deck date
March 2021
Slide
62 of 144
Other recent decks by Alkermes
See all presentations (22 decks)
Investor Conference
January 2024
Results
October 2023
Investor Presentation
October 2023
Results
July 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io